|
|
|
|
|
|
|
|
|
|
|
|
|
|
Previous: PROGENICS PHARMACEUTICALS INC, 10-Q, 2000-11-13 |
Next: INTERVEST CORPORATION OF NEW YORK, 10-Q, 2000-11-13 |
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This Schedule contains summary financial information extracted from the
Financial Statements of Progenics Pharmaceuticals, Inc. at September 30, 2000
and is qualified in its entirety by reference to such Financial
Statements.
</LEGEND>
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> DEC-31-2000
<PERIOD-START> JAN-01-2000
<PERIOD-END> SEP-30-2000
<CASH> 11,705,138
<SECURITIES> 52,025,892
<RECEIVABLES> 2,680,116
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 51,748,884
<PP&E> 4,423,363
<DEPRECIATION> 2,600,087
<TOTAL-ASSETS> 68,611,352
<CURRENT-LIABILITIES> 1,581,051
<BONDS> 0
0
0
<COMMON> 15,828
<OTHER-SE> 66,573,034
<TOTAL-LIABILITY-AND-EQUITY> 68,611,352
<SALES> 0
<TOTAL-REVENUES> 10,426,453
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 13,808,954
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 71,279
<INCOME-PRETAX> (3,453,780)
<INCOME-TAX> 0
<INCOME-CONTINUING> (3,453,780)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (3,453,780)
<EPS-BASIC> (.29)
<EPS-DILUTED> (.29)
</TABLE>
|
|